BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Misses Estimates By $3.04 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) posted its earnings results on Wednesday. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04), FiscalAI reports. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The firm had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. During the same quarter in the prior year, the firm earned $0.20 earnings per share. The business’s revenue for the quarter was up 7.5% on a year-over-year basis.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• Strong commercial momentum: ORLADEYO net revenue was $148.3 million in Q1, with monthly new patient prescriptions slightly ahead of 2025 averages and early pediatric launch demand observed across all four pellet strengths.
• A manufacturing issue with ORLADEYO pediatric pellets will delay initial product fulfillment; the company says it does not expect the delay to change 2026 revenue guidance and will provide more timing details later this quarter.
• Development progress for navenibart is ahead of plan: ALPHA-ORBIT pivotal enrollment should complete by end of next month at ~145 patients, keeping a U.S. filing target by the end of 2027 and supporting a sizable injectable opportunity.
• Pipeline expansion: BCX17725 (KLK5 inhibitor) has started dosing in Part 4 of Phase I (up to 12 patients) with proof-of-concept data expected by year-end for Netherton syndrome.
• Mixed financial picture: GAAP was impacted by an in-process R&D charge of $698 million from the Astria asset acquisition, while non-GAAP results show strong operating profitability and pro forma liquidity of roughly $331 million after a $70 million upfront European license and a $400 million credit facility.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX traded down $0.15 during mid-day trading on Thursday, reaching $8.68. The company’s stock had a trading volume of 923,623 shares, compared to its average volume of 5,050,708. The stock has a 50-day moving average of $9.05 and a two-hundred day moving average of $7.81. The stock has a market capitalization of $2.21 billion, a P/E ratio of 7.25 and a beta of 0.57. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.31.

Insider Activity at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 150,000 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the sale, the insider directly owned 400,703 shares in the company, valued at $3,666,432.45. This represents a 27.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Invesco Ltd. raised its position in shares of BioCryst Pharmaceuticals by 40.8% in the fourth quarter. Invesco Ltd. now owns 1,354,897 shares of the biotechnology company’s stock valued at $10,568,000 after buying an additional 392,521 shares during the last quarter. Mackenzie Financial Corp raised its position in shares of BioCryst Pharmaceuticals by 16.6% in the fourth quarter. Mackenzie Financial Corp now owns 150,728 shares of the biotechnology company’s stock valued at $1,152,000 after buying an additional 21,411 shares during the last quarter. NewEdge Advisors LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $390,000. XTX Topco Ltd acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $133,000. Finally, Vestal Point Capital LP acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $17,550,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of research analyst reports. Needham & Company LLC reduced their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday. Evercore initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective for the company. Royal Bank Of Canada reduced their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Finally, Weiss Ratings upgraded shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Wednesday, March 4th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $20.10.

Trending Headlines about BioCryst Pharmaceuticals

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q1 revenue topped estimates and ORLADEYO sales showed healthy growth — Q1 revenue was ~$156.4M versus consensus ~$151.1M, and ORLADEYO net revenue was $148.3M (up ~11% y/y; +21% on a comparable basis excluding Europe). This supports the company’s commercial momentum. BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Management hosted an earnings call outlining pipeline progress and growth plans — investors may view the call highlights as confirmation of commercial execution and future catalysts. BioCryst Earnings Call: Growth, Pipeline And New Risks
• Neutral Sentiment: FY‑2026 revenue guidance set to $635M–$660M, which is roughly in line with consensus (~$648.7M). The range gives some visibility to the year but is not a clear beat. Q1 Slide Deck / Press Materials
• Neutral Sentiment: Needham reduced its price target from $18 to $16 but kept a Buy rating — this lowers upside expectations slightly while still signaling confidence in longer‑term value. Needham price target note (via Benzinga / TickerReport)
• Negative Sentiment: Large GAAP EPS miss and confusing EPS metrics drove selling — sources show GAAP EPS was deeply negative (widely reported as a sizable loss due to one‑time/non‑cash items), even though adjusted results and revenue beat estimates. That headline EPS miss is the primary reason the stock declined. BioCryst Q1 press release / transcript (MarketBeat)
• Negative Sentiment: Market reaction also reflects mixed analyst takeaways and low intraday volume, so price moves may be volatile until investors parse GAAP vs adjusted results and pipeline timelines. BCRX Q1 coverage (Zacks)

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.